Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
3(18%)
Results Posted
43%(3 trials)

Phase Distribution

Ph phase_1
2
12%
Ph phase_2
5
29%
Ph not_applicable
10
59%

Phase Distribution

2

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution17 total trials
Phase 1Safety & dosage
2(11.8%)
Phase 2Efficacy & side effects
5(29.4%)
N/ANon-phased studies
10(58.8%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

3

trials recruiting

Total Trials

17

all time

Status Distribution
Active(4)
Completed(7)
Terminated(1)
Other(5)

Detailed Status

Completed7
unknown5
Recruiting2
Withdrawn1
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
17
Active
3
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (11.8%)
Phase 25 (29.4%)
N/A10 (58.8%)

Trials by Status

recruiting212%
completed741%
withdrawn16%
not_yet_recruiting16%
unknown529%
active_not_recruiting16%

Recent Activity

Clinical Trials (17)

Showing 17 of 17 trials
NCT02756793Not Applicable

Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial)

Active Not Recruiting
NCT04037358Phase 2

RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers

Completed
NCT06918951Not Applicable

Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers

Recruiting
NCT06585878Not Applicable

A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic Renal Cell Carcinoma

Not Yet Recruiting
NCT03673176Not Applicable

Lung Volume Reduction for Severe Emphysema by Stereotactic Ablative Radiation Therapy

Completed
NCT02414334Not Applicable

SABR-SCAN Trial for Pulmonary Oligometastases

Completed
NCT05084391Phase 1

Phase I/II Randomized Study of Stereotactic Ablative Radiotherapy (SABR) Versus Standard of Care for Refractory Structural Cardiac Arrhythmias (SABR-HEART)

Withdrawn
NCT03486431Not Applicable

A Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy for Non-spine Bone & Lymph Node Oligometastates

Completed
NCT01871454Phase 2

Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers

Recruiting
NCT02791503Not Applicable

CROSSFIRE Trial: Comparing the Efficacy of Irreversible Electroporation With Radiotherapy

Completed
NCT03349892Not Applicable

Stereotactic Ablative Radiotherapy for Refractory Ventricular Tachycardia

Completed
NCT02921139Not Applicable

Comparing Re-TACE Versus SABR for Post-prior-TACE Incompletely Regressed HCC: a Randomized Controlled Trial (TASABR)

Unknown
NCT04948034Phase 2

The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)

Unknown
NCT04535024Phase 2

The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer

Unknown
NCT04625894Phase 1

The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in Oligometastatic Gastrointestinal Cancer

Unknown
NCT02629458Not Applicable

A Study to Determine the Feasibility and Acceptability of Conducting a Phase III Randomised Controlled Trial Comparing Stereotactic Ablative Radiotherapy With Surgery in paTients With Peripheral Stage I nOn-small Cell Lung Cancer cOnsidered Higher Risk of Complications From Surgical Resection

Completed
NCT02584699Phase 2

Study of Stereotactic Ablative Radiotherapy (SABR) in Elderly Stage I NSCLC

Unknown

All 17 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
17